AbbVie Inc. $ABBV is Meadowbrook Wealth Management LLC’s 4th Largest Position

Meadowbrook Wealth Management LLC lifted its holdings in AbbVie Inc. (NYSE:ABBV) by 30.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 21,639 shares of the company’s stock after acquiring an additional 5,050 shares during the quarter. AbbVie comprises about 5.6% of Meadowbrook Wealth Management LLC’s investment portfolio, making the stock its 4th largest position. Meadowbrook Wealth Management LLC’s holdings in AbbVie were worth $4,944,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. Ellenbecker Investment Group grew its holdings in AbbVie by 0.8% during the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after purchasing an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA raised its holdings in AbbVie by 0.3% in the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after purchasing an additional 45 shares during the period. Matthew Goff Investment Advisor LLC raised its holdings in AbbVie by 0.3% in the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after purchasing an additional 45 shares during the period. Centennial Wealth Advisory LLC boosted its position in shares of AbbVie by 2.2% during the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after purchasing an additional 45 shares in the last quarter. Finally, Willner & Heller LLC boosted its position in shares of AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock worth $1,759,000 after purchasing an additional 46 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Price Performance

Shares of AbbVie stock opened at $204.86 on Wednesday. The firm has a market cap of $362.23 billion, a price-to-earnings ratio of 86.81, a price-to-earnings-growth ratio of 0.71 and a beta of 0.34. The stock’s 50-day moving average is $222.48 and its 200-day moving average is $224.74. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period last year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase‑1 obesity data for ABBV‑295: AbbVie reported dose‑dependent, meaningful weight loss from ABBV‑295 (a long‑acting amylin analog), marking the company’s formal entry into the anti‑obesity market and diversifying revenue beyond immunology and oncology — a potentially material long‑term growth driver if later‑stage trials succeed. AbbVie’s ABBV-295 Obesity Data Opens New Non Incretin Opportunity
• Positive Sentiment: Multi‑year MLB partnership expands “Striking Out Cancer” nationally: AbbVie was named the Official Pharmaceutical Partner of Major League Baseball, amplifying its cancer‑support initiative, broadening brand reach and CSR impact (each MLB strikeout triggers donations to Stand Up To Cancer). This raises AbbVie’s consumer visibility and may help patient‑facing positioning. AbbVie Named Official Pharmaceutical Partner of Major League Baseball (PR Newswire) MLB: AbbVie named official pharmaceutical partner
• Positive Sentiment: Recent fundamentals and legal risk reduction support the story: AbbVie beat top‑line estimates in its latest quarter, raised FY‑2026 guidance, and a Bloomberg Law report shows the company prevailed in a worker’s suit over family‑medical‑history queries — reducing a potential legal overhang. These items support earnings visibility and dividend stability. AbbVie to sponsor leading US baseball league AbbVie beats worker’s suit (Bloomberg Law)
• Neutral Sentiment: Positive media/analyst commentary on valuation: Several outlets (The Motley Fool, Kalkine) highlight AbbVie’s dividend, revenue growth and argue the stock looks attractively valued, which may support longer‑term investor interest but is not an immediate catalyst. Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now AbbVie Shares Rise on Revenue Growth (Kalkine)
• Negative Sentiment: Valuation and technical/financial quirks may limit near‑term upside: AbbVie trades below its 50‑ and 200‑day moving averages and shows a high reported P/E (~86.8) and a negative ROE figure (accounting effect), factors that can pressure sentiment and constrain multiple expansion until growth visibility improves. MarketBeat ABBV snapshot

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a research note on Wednesday, January 28th. Piper Sandler increased their price target on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Royal Bank Of Canada began coverage on AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target on the stock. Finally, Berenberg Bank set a $275.00 price objective on AbbVie in a report on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

Insider Buying and Selling

In other news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.08% of the stock is owned by company insiders.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.